Michael Amos

Dr. Michael D. Amos is the Biosciences Advisor to the Director of the Chemical Science and Technology Laboratory (CSTL). Mike’s graduate area of emphasis was in microbiology and immunology and his thesis research was in regulatory networks of the immune system. 

From there, he furthered his training at the University of Alabama at Birmingham, College of Medicine as a postdoctoral fellow in the Departments of Microbiology and Rheumatology, studying the molecular immunology of rheumatoid arthritis.

He has held various industry research, marketing and business development positions in the fields of biopharmaceuticals, neutraceuticals, drug delivery, transgenics, immunodiagnostics, molecular biology and molecular pathology. He is also a founder of two biotechnology companies.

Dr. Amos joined NIST in 2002 as a Program Manager and Biologist in the Chemistry and Life Sciences Office of the Advanced Technology Program (ATP), an extramural funding arm of NIST. At ATP, he participated and led evaluation of biotechnology proposals for funding and managed projects on stem cells, nanotechnology, immunotherapeutics, cancer vaccines, neurobiology, protein therapeutics, drug discovery, gene therapy, metabolic engineering, and medical devices.

Mike joined CSTL in 2006, and serves as biosciences advisor to Dr. Willie May as a liaison to industry, academia and other government agencies in the bioscience and health care areas.

Dr. Amos serves as the Department of Commerce representative on the Department of Health and Human Services Secretary’s Advisory Committee on Genetic, Health and Society (SACGHS). Dr. Amos is a leader in the field of autoimmune immunodiagnostics and serves on the Autoimmune Disease Coordinating Committee of the National Institutes of Health.